Omission of Group in Byline and Clinical Trial Sites and Investigators in: Safety and Efficacy Assessment of Chimeric Ribozyme to Proliferating Cell Nuclear Antigen to Prevent Recurrence of Proliferative Vitreoretinopathy

Omission of Group in Byline and Clinical Trial Sites and Investigators. In the Clinical Trials article titled “Safety and Efficacy Assessment of Chimeric Ribozyme to Proliferating Cell Nuclear Antigen to Prevent Recurrence of Proliferative Vitreoretinopathy,” published in the September 2007 issue of the Archives (2007;125[9]:1161-1167), “for the IM-VIT100 Study Group” was omitted from the byline. Also, the list of clinical trial sites and investigators was omitted and now appears in the online version of the article. The authors apologize for the oversight.